HLB Co., Ltd.

KOSDAQ 028300.KQ

HLB Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: -36.09%

HLB Co., Ltd. Return on Equity (ROE) is -36.09% for the year ending December 31, 2023, a -194.58% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

HLB Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was -12.25%, a 45.57% change year over year.
HLB Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was -22.51%, a -34.82% change year over year.
HLB Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was -16.69%, a 30.46% change year over year.
HLB Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was -24.01%, a -265.47% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

KOSDAQ: 028300.KQ

HLB Co., Ltd.

CEO	Mr. Jung-Min Park
IPO Date	Dec. 24, 2008
Location	South Korea
Headquarters	216-53, Dangwol-ro
Employees	150
Sector	Industrials
Industries Shipbuilding Pharmaceuticals

Description

HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.

Key trends

Past 5 years